Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 26, Issue 3, pp 223–226 | Cite as

Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma

  • Jaffer A. Ajani
  • David M. Ota
  • V. Bruce Grossie
  • James L. Abbruzzese
  • Jack S. Faintuch
  • Yehuda Z. Patt
  • Diane E. Jackson
  • Bernard Levin
  • Kenji Nishioka
Article

Summary

A total of 32 evaluable patients with measurable advanced colorectal carcinoma were treated with continuous-infusion alpha-difluoromethylomithine (DFMO) at a median daily dose of 8 g/m2 (range, 6–14 g/m2). DFMO was infused over 24 h daily for 28 days, followed by a rest period of 7 days. Of the 32 patients, 14 had received no prior chemotherapy. A total of 65 courses was given, with the median being 2 (range, 1–9 courses). None of the patients achieved a partial or complete response; however, 3 patients achieved a minor response and 14 had stable disease. The frequent toxic effects of DFMO included thrombocytopenia (which was dose-limiting), malaise, nausea, vomiting, reversible hearing loss, and diarrhea. Our data suggest that continuous-infusion DFMO therapy is feasible and results in only mild gastrointestinal toxicity. Although DFMO proved to be ineffective as a single agent in this trial, it could probably best be used in combination with cytotoxic agents known to enhance its antitumor activity in a preclinical setting.

Keywords

Polyamine Metabolism Polyamine Synthesis Carcino Embryonic Antigen Level Median Daily Dose Advanced Colorectal Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abeloff MD, Slavik M, Luk GD, Griffin CA, Hermann J, Blanc O, Sjoerdsma A, Baylin SB (1984) Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine. An inhibitor of polyamine synthesis. J Clin Oncol 2: 124–130PubMedGoogle Scholar
  2. 2.
    Ajani JA, Ota DM, Grossie VB, Levin B, Nishioka K (1989) Alterations in polyamine metabolism during continuous intravenous infusion of alpha-difluoromethylornithine: correlation of thrombocytopenia with alpha-difluoromethylornithine plasma levels. Cancer Res 49: 5761–5765PubMedGoogle Scholar
  3. 3.
    Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH (1989) Comprehensive criteria for therapy-induced toxicity. Cancer Invest 8: 141–153Google Scholar
  4. 4.
    Bjerkvig R, Oredsson SM, Marton LJ, Linden M, Deen DF (1983) Cell cycle age response of 9L cells to 1,3-bis(2-chloroethyl)-1-nitrosourea and modification by alpha-difluoromethylornithine. Cancer Res 43: 1497–1500PubMedGoogle Scholar
  5. 5.
    Ducore JM, McNamara L (1986) Effect of alpha-difluoromethylornithine onl-phenylalanine mustard-induced cytotoxicity and DNA interstrand cross-linking in a human cell line in vitro. Cancer Res 46: 1068–1072PubMedGoogle Scholar
  6. 6.
    Grossie VB, Ota DM, Ajani JA, Nishioka K (1987) Effect of intravenous alpha-difluoromethylornithine on the polyamine levels of normal tissue and transplantable fibrosarcoma. Cancer Res 47: 1836–1840PubMedGoogle Scholar
  7. 7.
    Grossie VB, Ota DM, Ajani JA, Chang TH, Patenia D, Nishioka K (1989) Reduction of difluoromethyl-ornithine-induced thrombocytopenia with ornithine while maintaining anti-tumor activity. Cancer Res 49: 4159–4162PubMedGoogle Scholar
  8. 8.
    Herr HW, Kleinert EL, Relyea NM, Whitmore WF (1984) Potentiation of methylglyoxal-bis-guanylhydrazone by alpha-difluoromethylornithine in rat prostate cancer. Cancer 53: 1294–1298PubMedCrossRefGoogle Scholar
  9. 9.
    Luk GD, Goodwin G, Marton LJ, Baylin SB (1981) Polyamines are needed for the survival of human small-cell lung carcinoma in culture. Proc Natl Acad Sci USA 78: 2355–2358PubMedCrossRefGoogle Scholar
  10. 10.
    Maddox AM, Keating MJ, McCredie KE, Estey E, Freireich EJ (1985) Phase I study of intravenous difluoromethylornithine — a polyamine inhibitor. Invest New Drugs 3: 287–292PubMedCrossRefGoogle Scholar
  11. 11.
    Mamont PS, Duchesne MC, Grove J, Bey P (1978) Antiproliferative properties ofDL-alpha-difluoromethyl ornithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylase. Biochem Biophys Res Commun 81: 58–66PubMedCrossRefGoogle Scholar
  12. 12.
    Mamont PS, Siat M, Joder-Ohlenbusch AM, Bernhardt A, Casara P (1984) Effect of (2R, 5R)-6-heptyne-2,5-diamine, a potent inhibitor ofl-ornithine decarboxylase, on rat hepatoma cells cultured in vitro. Eur J Biochem 142: 457–463PubMedCrossRefGoogle Scholar
  13. 13.
    McCann PP, Pegg AE, Sjoerdsma A (1987) Inhibition of polyamine metabolism. Biologic significance and basis for new therapies. Academic Press, Orlando, Florida, pp 1–371Google Scholar
  14. 14.
    Pegg AE (1986) Recent advances in the biochemistry of polyamines in eukaryotes. Biochem J 234: 249–262PubMedGoogle Scholar
  15. 15.
    Pegg AE (1988) Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res 48: 759–774PubMedGoogle Scholar
  16. 16.
    Pegg AE, McCann PP (1982) Polyamine metabolism and function. Am J Physiol 243: C212-C221PubMedGoogle Scholar
  17. 17.
    Pegg AE, Wechter RS, Clark RS, Wiest L, Erwin BG (1986). Acetylation of decarboxylatedS-adenosylmethionine by mammalian cells. Biochemistry 25: 379–384PubMedCrossRefGoogle Scholar
  18. 18.
    Pera PJ, Kramer DL, Sufrin JR, Porter CW (1986) Comparison of the biological effects of four irreversible inhibitors of ornithine decarboxylase in two murine lymphocytic leukemia cell lines. Cancer Res 46: 1148–1154PubMedGoogle Scholar
  19. 19.
    Seidenfeld J, Komar KA (1985) Chemosensitization of cultured human carcinoma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea by difluoromethylornithine-induced polyamine depletion. Cancer Res 45: 2132–2138PubMedGoogle Scholar
  20. 20.
    Seidenfeld J, Gray JW, Marton LJ (1981) Depletion of 9L rat brain cell polyamine content by treatment withD,L-alpha-difluoromethylornithine inhibits proliferation and the G1 to S transition. Exp Cell Res 131: 209–216PubMedCrossRefGoogle Scholar
  21. 21.
    Sjoerdsma A, Schechter PJ (1984) Chemotherapeutic implications of polyamine biosynthesis inhibition. Clin Pharmacol Ther 35: 287–300PubMedGoogle Scholar
  22. 22.
    Splinter TAW, Romjin JC (1986) Phase I study of alpha-difluoromethylornithine and methyl-GAG. Eur J Clin Oncol 22: 61–67CrossRefGoogle Scholar
  23. 23.
    Sunkara PS, Fowler SK, Nishioka K, Rao PN (1980) Inhibition of polyamine biosynthesis by alpha-difluoromethylornithine potentiates the cytotoxic effects of arabinosyl cytosine in HeLa cells. Biochem Biophys Res Commun 95: 423–430PubMedCrossRefGoogle Scholar
  24. 24.
    Tabor CW, Tabor H (1984) Polyamines. Annu Rev Biochem 53: 749–790PubMedCrossRefGoogle Scholar
  25. 25.
    Tabor CW, Tabor H (1985) Polyamines in microorganisms. Microbiol Rev 49: 81–99PubMedGoogle Scholar
  26. 26.
    Warrell RP, Coonley CJ, Burchenal JH (1983) Sequential inhibition of polyamine synthesis: a phase I trial of DFMO (alpha-difluoromethylornithine) and methyl-GAG[methylglyoxal-bis(guanylhydrazone)]. Cancer Chemother Pharmacol 11: 134–136PubMedCrossRefGoogle Scholar
  27. 27.
    Williams-Ashman HG, Canellakis ZN (1979) Polyamines in mammalian biology and medicine. Perspect Biol Med 22: 421–453PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Jaffer A. Ajani
    • 2
  • David M. Ota
    • 1
  • V. Bruce Grossie
    • 1
  • James L. Abbruzzese
    • 2
  • Jack S. Faintuch
    • 2
  • Yehuda Z. Patt
    • 2
  • Diane E. Jackson
    • 2
  • Bernard Levin
    • 2
  • Kenji Nishioka
    • 1
  1. 1.Departments of General SurgeryThe University of Texas M. D. Anderson Cancer CenterHoustonUSA
  2. 2.Department of Medical OncologyM. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations